Form 4 MetaVia Inc. For: Oct 12 Filed by: Browne Sarah Kaplan

Tue, 13 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261013/27181146.html

Form 3 MetaVia Inc. For: Oct 12 Filed by: Browne Sarah Kaplan

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181114.html

Form 8-K MetaVia Inc. For: Oct 13

Tue, 13 Oct 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20261013/27177918.html

MetaVia names Sarah Browne as chief medical officer

Tue, 13 Oct 2026 08:31:21 -0400

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company, announced the appointment of Sarah Browne, M.D., as Chief Medical Officer, effective October 12, 2026.

Dr. Browne brings more than 20 years of experience in clinical development, regulatory science, and clinical medicine, with a focus on liver and metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH).

Most recently, Dr. Browne served as a clinical development consultant to Soufflé Therapeutics. Before that, she held the role of Vice President of Clinical Development at Altimmune, Inc., where she led programs in obesity, metabolic, and liver diseases. Her work included advancing pemvidutide, a dual GLP-1/glucagon receptor agonist, from

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

Tue, 13 Oct 2026 08:31:00 -0400

Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development

Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide

CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ --

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

Tue, 13 Oct 2026 08:31:00 -0400

Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development

Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide

CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ --

MetaVia Inc. (MTVA) Tops Q2 EPS by 73c

Fri, 07 Aug 2026 08:56:17 -0400

MetaVia Inc. (NASDAQ: MTVA) reported Q2 EPS of ($0.09), $0.73 better than the analyst estimate of ($0.82).
For earnings history and earnings-related data on MetaVia Inc. (MTVA) click here.

Form 10-Q MetaVia Inc. For: Jun 30

Thu, 06 Aug 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260806/26884607.html

Form 10-Q MetaVia Inc. For: Jun 30

Thu, 06 Aug 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260806/26884607.html

Form 8-K MetaVia Inc. For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260806/26883702.html

Form 8-K MetaVia Inc. For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260806/26883702.html

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:05:00 -0400

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726
16-Week Topline Data Expected in the Fourth Quarter of 2026
CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update.

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:05:00 -0400

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726
16-Week Topline Data Expected in the Fourth Quarter of 2026
CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update.

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:05:00 -0400

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726
16-Week Topline Data Expected in the Fourth Quarter of 2026
CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update.

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 16:05:00 -0400

All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726
16-Week Topline Data Expected in the Fourth Quarter of 2026
CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update.

H.C. Wainwright Reiterates Buy Rating on MetaVia (MTVA)

Fri, 10 Jul 2026 06:50:46 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $20.00 price target on MetaVia (NASDAQ: MTVA).
The analyst commented: "MetaVia announced that all active patients in both the Part 3a and 3b cohorts have successfully reached the highest target doses of 48 mg and 64 mg. We view the update as modestly positive, but mainly as a titration and execution milestone ahead of the more important 4Q26 topline readout. The key takeaway is that DA-1726 appears able to reach higher exposure levels without an obvious early tolerability ceiling, although this is not the same as completed 64 mg efficacy or

Form 8-K MetaVia Inc. For: Jul 09

Thu, 09 Jul 2026 08:36:00 -0400
si-local-file:///var/storage/secattach/20260709/26750759.html

Form 8-K MetaVia Inc. For: Jul 09

Thu, 09 Jul 2026 08:36:00 -0400
si-local-file:///var/storage/secattach/20260709/26750759.html

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

Thu, 09 Jul 2026 08:31:22 -0400

MetaVia Inc. (Nasdaq: MTVA) announced that all active patients enrolled in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity treatment have completed dose titration and are now receiving their highest target doses across both study cohorts.

Part 3 of the Phase 1 program consists of two 16-week titration cohorts. In Part 3A, patients titrated from 16 mg to 48 mg. In Part 3B, patients titrated from 16 mg to 32 mg and then to 64 mg. The trial has a planned enrollment of approximately 40 obese adult subjects, with roughly 20 subjects per cohort, randomized at a

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

Thu, 09 Jul 2026 08:31:22 -0400

MetaVia Inc. (Nasdaq: MTVA) announced that all active patients enrolled in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for obesity treatment have completed dose titration and are now receiving their highest target doses across both study cohorts.

Part 3 of the Phase 1 program consists of two 16-week titration cohorts. In Part 3A, patients titrated from 16 mg to 48 mg. In Part 3B, patients titrated from 16 mg to 32 mg and then to 64 mg. The trial has a planned enrollment of approximately 40 obese adult subjects, with roughly 20 subjects per cohort, randomized at a

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg
Topline Data Remains on Track for Fourth Quarter 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg
Topline Data Remains on Track for Fourth Quarter 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg
Topline Data Remains on Track for Fourth Quarter 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Thu, 09 Jul 2026 08:31:00 -0400

All Active Patients in Both Cohorts Have Successfully Reached Highest Target Doses of 48 mg and 64 mg
Topline Data Remains on Track for Fourth Quarter 2026
CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial evaluating DA-1726 for the treatment of obesity have successfully completed dose titration and are now receiving their highest target doses in both study cohorts. DA-1726 is a novel

Form 8-K MetaVia Inc. For: Jul 02

Thu, 02 Jul 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260702/26727649.html

StreetInsider.com News Articles

Form 4 MetaVia Inc. For: Oct 12 Filed by: Browne Sarah Kaplan

Form 3 MetaVia Inc. For: Oct 12 Filed by: Browne Sarah Kaplan

Form 8-K MetaVia Inc. For: Oct 13

MetaVia names Sarah Browne as chief medical officer

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

MetaVia Inc. (MTVA) Tops Q2 EPS by 73c

Form 10-Q MetaVia Inc. For: Jun 30

Form 10-Q MetaVia Inc. For: Jun 30

Form 8-K MetaVia Inc. For: Aug 06

Form 8-K MetaVia Inc. For: Aug 06

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

H.C. Wainwright Reiterates Buy Rating on MetaVia (MTVA)

Form 8-K MetaVia Inc. For: Jul 09

Form 8-K MetaVia Inc. For: Jul 09

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

MetaVia completes dose titration in Phase 1 Part 3 obesity trial

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

Form 8-K MetaVia Inc. For: Jul 02